-- 澳新銀行研究部週五表示,受石油危機陰影籠罩,紐西蘭4月份消費者信心跌至近三年來的最低水平,引發了人們對整體經濟前景和零售商下行風險的擔憂。 澳新銀行-羅伊摩根消費者信心指數4月從3月的91.3下降11點至80.3。自從中東衝突爆發並推高全球燃油價格以來,該指數在過去兩個月已累積下降20點。 通膨預期再次上升約1個百分點至6.6%。認為「現在是購買大型家用物品的好時機」的家庭淨比例下降11個百分點至-25,為2024年9月以來的最低水準。 該機構表示,石油危機尚未對家庭收入產生實質影響,消費者信心下降反映的是生活成本上升,以及零售商對未來業務活動的擔憂日益加劇。 然而,由於汽油價格上漲影響了每週預算,消費者信心目前已降至2022年和2023年的水平,顯然正在受到打擊。 央行補充說,雖然消費者通膨預期並非其關注的重點,因為它們並未直接影響物價制定,但消費者通膨預期(6.6%)與企業薪資預期(2.5%)之間的差距正在擴大。
Related Articles
Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%
Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.
Zozo's Profit Climbs 6% in Fiscal Year 2025
Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.
EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure
EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.